Literature DB >> 9614921

Intron 3 of HMGIC is the most frequent target of chromosomal aberrations in human tumors and has been conserved basically for at least 30 million years.

B Kazmierczak, J Bullerdiek, K H Pham, S Bartnitzke, H Wiesner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9614921     DOI： 10.1016/s0165-4608(97)00348-8

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN： 0165-4608


× No keyword cloud information.
  6 in total

Review 1.  Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins.

Authors:  M Bustin
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

2.  Molecular characterization of the mouse In(10)17Rk inversion and identification of a novel muscle-specific gene at the proximal breakpoint.

Authors:  Kathleen F Benson; Kiran Chada
Journal:  Genetics       Date:  2002-01       Impact factor: 4.562

3.  The long non-coding RNA LSINCT5 promotes malignancy in non-small cell lung cancer by stabilizing HMGA2.

Authors:  Yuheng Tian; Nali Zhang; Shuwen Chen; Yuan Ma; Yanyan Liu
Journal:  Cell Cycle       Date:  2018-07-05       Impact factor: 4.534

4.  Constitutional rearrangement of the architectural factor HMGA2: a novel human phenotype including overgrowth and lipomas.

Authors:  Azra H Ligon; Steven D P Moore; Melissa A Parisi; Matthew E Mealiffe; David J Harris; Heather L Ferguson; Bradley J Quade; Cynthia C Morton
Journal:  Am J Hum Genet       Date:  2004-12-10       Impact factor: 11.025

5.  Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers.

Authors:  Xiaochen Wang; Xiyong Liu; Angela Ying-Jian Li; Lirong Chen; Lily Lai; Her Helen Lin; Shuya Hu; Lifang Yao; Jiaping Peng; Sofia Loera; Lijun Xue; Bingsen Zhou; Lun Zhou; Shu Zheng; Peiguo Chu; Suzhan Zhang; David Kong Ann; Yun Yen
Journal:  Clin Cancer Res       Date:  2011-01-20       Impact factor: 12.531

6.  Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer.

Authors:  C Langelotz; P Schmid; C Jakob; U Heider; K D Wernecke; K Possinger; O Sezer
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.